thiazolidinedione

(redirected from Ciglitazone)
Also found in: Dictionary.

gli·ta·zone

(glit-ah'zōn),
Shorthand term for a class of oral hypoglycemics that have glitazone as a component in their names.
Synonym(s): thiazolidinedione

thiazolidinedione

(thī′ə-zō′lĭ-dēn′dĭ-ōn′)
n.
Any of a class of drugs that decrease insulin resistance and are used to treat type 2 diabetes.

thiazolidinedione

Glitazone, TZD Endocrinology A class of oral antidiabetic agents that inhibit tyrosine kinase, ↓ insulin resistance and correct hyperglycemia, hyperinsulinemia, hypertriglyceridemia Adverse effects Hepatic dysfunction. See Troglitazone, Tyrosine kinase inhibitor.

thiazolidinedione

(thī′ă-zŏ″lĭ-dēn-dī-ŏn)
A class of oral hypoglycemic agents that lowers blood sugars by reducing insulin resistance (improving tissue sensitivity to the effects of insulin) in fat and muscle, as well as the liver. A commonly used agent in this class is pioglitazone.

CAUTION!

Side effects of medications in this class include increased fluid retention, fractures, heart failure, liver injury, and weight gain.
References in periodicals archive ?
Ge, "A protective role of ciglitazone in ox-LDL-induced rat microvascular endothelial cells via modulating PPAR[gamma]-dependent AMPK/eNOS pathway," Journal of Cellular and Molecular Medicine, vol.
All 3 drugs--lovastatin, ciglitazone, and candesartan--caused significant inhibition of TNF-[alpha] release.
Englitazone, ciglitazone, and pioglitazone are the newest additions to this family of drugs, and are currently under study in clinical trials (Bajaj & Simonson, 1997; Janeway et al.
2006) and the peroxisome proliferator-activated receptor-[gamma] ligand ciglitazone (Chen and Harrison 2005), both xenobiotics that induce NF-[kappa]B activation, have been shown to include p65 phosphorylation.
The three agents currently under investigation are troglitazone (Rezulin[R]), pioglitazone, and ciglitazone (Garber & Gavin, 1996).